DrGee is presented, an essentiality-centered platform that infers drug sensitivity solely from gene expression profiles, and the built-in DeepEEAA model integrates gene expression, gene essentiality, drug-protein affinity, and drug-gene associations to quantitatively predict IC50 values.
Abstract
Summary Precision oncology relies on tumor molecular profiles to predict drug responses. Instead of using conventional molecular features directly, we construct predictive signatures based on gene essentiality. Here, we present DrGee, an essentiality-centered platform that infers drug sensitivity solely from gene expression profiles. The built-in DeepEEAA model integrates gene expression, gene essentiality, drug-protein affinity, and drug-gene associations to quantitatively predict IC50 values. DeepEEAA achieved competitive predictive performance on independent cell line datasets (R2 = 0.764; MSE = 0.9345), outperforming recent benchmark deep learning methods. DrGee prioritized four candidate drugs for the 95-D lung cancer cell line, among which BI-97C1 and trimetrexate were validated by in vitro assays and mouse xenograft experiments. Robust predictive performance was further confirmed in OVCAR8 ovarian cancer cells. In TCGA cohorts, essentiality-driven predictions stratified patients with significantly different overall survival outcomes (AUC-PR = 0.825), highlighting the translational potential of DrGee.
Accurate prediction of drug sensitivity in cancer cell lines is vital for precision oncology and patient-specific therapies. However, many computational approaches fail to integrate multi-modal biological and chemical features and often struggle with high-dimensional, imbalanced pharmacogenomic data, limiting predictive accuracy and interpretability. To address these challenges, we developed a machine learning framework that integrates pharmacogenomic profiles-including mutation status, copy number alterations, and microsatellite instabil-ity-with molecular fingerprints and descriptors of 85 anticancer drugs, generated using PaDEL from SMILES strings. Data from 40 breast cancer cell lines in the Genomics of Drug Sensitivity in Cancer (GDSC) dataset were employed. A threestage feature selection strategy combining Boruta, mRMR, and XGBoost was applied to reduce drug feature dimensionality while retaining 130 cell line features. Multiple models were trained, and LightGBM, optimized with grid search, class weighting, and 3-fold cross-validation, demonstrated superior performance in handling severe class imbalance (233 sensitive vs. 3167 resistant samples). LightGBM achieved training AUROC $=0.9455$, AUPRC $\boldsymbol{=} \mathbf{0. 5 1 4 8}$, Accuracy $\boldsymbol{=} \mathbf{0. 8 4 1 5}$, F1-score = 0.4481, Recall = 0.9409, and MCC = 0.4732, underscoring its suitability for sparse biomedical datasets. Model interpretation with SHapley Additive exPlanations (SHAP) highlighted BRCA-related features, identifying cnaBRCA25 (not mutated) as a resistance marker and cnaBRCA47 (mutated) as a context-dependent biomarker, consistent with their roles in DNA repair pathways. Overall, this framework demonstrates the value of multi-modal integration and interpretable machine learning in pharmacogenomics. While results are promising, validation on larger and independent cohorts is essential to establish clinical relevance.
D. Kumari, Aiman, Sakshi Singh et al.· Annual International Compute...· 0 citations
This study demonstrates that multi-omics integration via machine learning enhances survival prediction and reveals actionable biomarkers in breast cancer and outperformed mutation-based models.
G. Mestrallet, Alexandre Pierga, P. Frémont et al.· 0 citations
It is suggested that glycolytic activity is closely associated with both drug resistance and clinical prognosis in LUAD, and the proposed integrative model holds promise for enhancing precision treatment decision-making through optimized risk assessment and rational selection of chemotherapeutic regimens.
Qian Zheng, Yunxiao Liu, Tianli Li et al.· Frontiers in Oncology· 0 citations
Precision oncology seeks to match each tumor with the most effective anti-cancer therapy. Advances in pharmacogenomics and machine learning enabled drug response prediction models with strong performance in cancer cell lines. Nonetheless, patient-centric evaluation of drug prioritization and systematic assessment of model generalization in patient-derived systems across cancer types remain largely absent. Here we introduce a translational framework combining patient-centric benchmarking with a pan-cancer pharmacogenomic atlas of patient-derived organoids, together with NELLY, a deep learning model integrating transcriptomic and chemical information to predict drug response and prioritize therapies. NELLY outperformed existing methods for patient-specific drug prioritization across cancer cell lines and patient-derived organoids, including under out-of-distribution evaluation. Its dynamic weighting mechanism provided patient-specific gene attributions, offering a route to connect predicted drug response to molecular programs associated with drug resistance. Our results support NELLY as a promising framework for translationally relevant and interpretable drug response prediction in precision oncology.
C. Peralta Viteri, N. Harnischfeger, Lili Szabo et al.· bioRxiv· 0 citations
This study demonstrates the viability of the deep learning models to discover structurally novel anticancer agents that are distinct from conventional drugs, thereby expanding the therapeutic arsenal for TNBC patients.
Yiyue Xu, Taotao Dong, Butuo Li et al.· Journal of Chemical Informat...· 0 citations
This study developed a comprehensive strategy integrating computational predictions with in vitro experimental validations that reverses CDDP resistance in PROC by downregulating JUN, which dismantles intracellular pro-survival networks.
Chen Wang, Junfeng Guo, Taiyang Ye et al.· Frontiers in Pharmacology· 0 citations